HeartFlow®

Acquisition and Reconstruction Techniques for Coronary CT Angiography

Canon Medical Systems Scanner Platforms

Edited and Approved by

Jonathon Leipsic MD FSCCT
Past-President Society of Cardiovascular CT

331 E Evelyn Ave, Mountain View, CA 94041
ph: +1.650.241.1221 | info@heartflow.com | heartflow.com

15991228 V3

Table of Contents

1. Overview

Coronary computed tomography angiography (CCTA) is a non-invasive diagnostic for detecting coronary artery disease (CAD). CCTA is increasingly utilized in clinical practice for evaluating coronary anatomy for obstructive disease and plaque.

It is, however, imperative that artifact free CCTA image data is obtained in order for it to be successfully analyzed for anatomic assessment and/or to act as adequate input for adjunct analyses such as physiologic simulations. Data acquisition strategies and scanning protocols may vary depending on scanner manufacturer, system, and institutional preferences. This document provides references for reliable image acquisition for CCTA.

2. Introduction

Image acquisition in computed tomography is governed ultimately by the principle of As Low As Reasonably Achievable (ALARA). In the first 10 years of CCTA, the focus was almost exclusively on the detection of anatomical stenosis in low to intermediate risk patients. With the evolution of technology, the clinical utility of CCTA has extended beyond stenosis assessment to atherosclerosis characterization, the evaluation of structural heart disease, and the functional and physiological assessment of coronary stenoses. Recently the SCCT acquisition guidelines were updated and provide an excellent reference for Cardiac CT imaging specialists to help optimize their scan protocols. That being said, given the growing information that is provided from cardiac CT, the imaging requirements have evolved and require tailoring to meet the clinical indication. The purpose of this white paper is to highlight the parameters and image acquisition protocols that are important to help optimize image quality, provide accurate representation of anatomy and thus enable quantitative CT.

Importance of Heart Rate Control

With the advancements in scanner technology, the necessary requirement for heart rate reduction has decreased over time. The demands for a low and steady heart rate to ensure diagnostic image quality may not be what they once were but best practice remains to optimize image quality through heart rate control. SCCT guidelines recommend performing CCTA with heart rates below 60 bpm.

In addition, CCTA no longer simply provides stenosis evaluation but needs to enable the interpreting physician to identify and characterize plaque and, following the identification of a stenosis, to perform functional or physiologic evaluation. As a result, while latest generation CT scanners may enable diagnostic image quality at higher heart rates, there remains meaningful image quality benefits from heart rate reduction. In addition, lower heart rates allow the use of lower dose scan acquisitions that are not possible at higher heart rates. Heart rate control strategies are well established and the appropriate strategy is dependent on a number of variables including available medications, setting of practice and site preference. For recommendations please refer to the recently updated SCCT acquisition guidelines.

Importance of Nitrates

Nitrates as smooth muscle dilators have direct effect on coronary vasodilation and result in tangible enlargement of coronary size. As such, similar to invasive coronary catheterization, nitroglycerine (glyceryl trinitrate) should be administered prior to CCTA to optimize image quality and enable the most accurate stenosis evaluation. A commonly used regimen is 400-800 µg of sublingual nitroglycerin administered as either sublingual tablets or a metered lingual spray (commonly 1-2 tablets or 1-2 sprays) prior to the CCTA. While the evidence is modest and there is no randomized data, both a higher dose and administration via spray are becoming increasingly preferred in clinical practice and have been shown to help optimize coronary evaluation.

Selection of Tube Current and Potential

The scan parameters used for any cardiac CT should be tailored to the individual patient but also the intended application. The image quality issues with the greatest impact on the interpretability of CT are misalignment and image noise. As such, care must be given to ensure that image noise properties are appropriate and adequate for accurate lumen segmentation. To do so, tube current and potential should be selected carefully, guided by chest wall circumference, the iodine concentration of the intravenous contrast medium, and whether iterative reconstruction is available or not.

Iterative reconstruction (IR) has the ability to reduce image noise in CT without compromising the diagnostic quality of the CT image dataset, which permits a significant reduction in effective radiation dose. In current clinical practice, IR has enabled a significant reduction in radiation dose by allowing for a reduction in tube current and is now increasingly available across all cardiac capable CT scanners. IR commonly takes the form of a blended reconstruction of IR and filtered back projection (FBP). While a very helpful tool, care should be given when using a very high percentage of IR for quantitative CT analysis due to the potential impact on vessel segmentation.

3. Reference Protocol: Aquilion ONE, Aquilion ONE-Vision Edition, Aquilion ONE-GENESIS Edition, Aquilion ONE-PRISM Edition

1. Scanogram

General	Acquisition	Comments
Lateral and AP scout covering the heart and coronaries	• AP Scanogram: 120kVp/50mA • Lat Scanogram: 120kVp/100mA • Auto Voice (Breath hold command):  	Position the patient for AP scanogram to acquire AP and lateral scanograms. Offset the patient to the right so the heart is at the center of the scan field. Place the patient's arms above their head with the ECG leads outside the scan range. Attach the ECG Leads according to the manufacturer guidelines. • Ensure the ECG cables are clear of the gantry to prevent electronic interference • Perform an impedance check on ECG monitor to confirm good signal • Place an 18- or 20-guage IV cannula in the right antecubital vein. • Practice breath-holding with the patient at the tableside using the to ensure optimal compliance during the scan. Follow this link for an overview of the Ivy 7800 ECG monitor Have the patient practice breath-holding before starting the examination. This should be a single "breathe in and hold" command. The patient should be instructed to hold their breath at about 75% of maximum lung capacity ("take a comfortable breath in") and to take the same size breath each time they are told. This important step has two purposes: To ensure that the patient can hold their breath for the required scan time. To monitor the patient's heart rate during breath-holding. Make sure that a steady heart rate is displayed with a clean ECG signal.

2. Non-enhanced Scan (optional)- Calcium Score

- Can be used for quantification of calcification
- Can be used for planning of subsequent contrast-enhanced data acquisition
- Volume data will be acquired as a single-beat/one rotation scan.
- Acquisition mode: Ca Score Volume Mode
- Tube Voltage: 120kVp
- SD: 60
- Min mA: 40
- Max mA: 300
- Target Slice Thickness: 0.5mm
- Rotation Time: 0.275 sec./ .350 sec (fastest available per system)
- Acquisition Thickness: 0.5mm
- DFOV: 250mm
- CFOV: Large
- Scan Direction: Superior-Inferior
- Prospective Acquisition: SURECardio will auto-select based on patient HR
- ≤70 BPM = 75% R-R
- ≥71 BPM = 40% R-R

DFOV: 250mm

- Volume Slice Thickness/Interval: 0.5 x 0.25
- SUREIQ: Ca Score
- Kernel: FC 12
- Recon Process: AIDR 3D Standard or AIDR 3D Enhanced
- Xact+: ON

3. ECG Gated CTA

a. kV and mA

General	Data Acquisition	Data Reconstruction
From the calcium scoring examination, select the start and end positions, the same scanogram can be used from the Calcium scan. It is advisable to plan 1 cm above the superior image selected and 1 cm below the inferior image selected in case the patient's breath-holding is inconsistent. Note: that the proximal LAD is often located superior to the origin of the left main coronary artery Can be used for quantification of calcification Click on the SURECardio button  Perform Breath Exercise • The system will prompt to perform a breath exercise to optimize acquisition parameters • SURECardio monitors the patient's heart rate during breath exercise. The acquisition parameters are optimized based on the HR detected during the breath hold • If the patient's heart rate changes by more than 10% during the breath exercise, perform additional breath exercise until the heart rate stabilizes. Be sure to give time for the patient to relax between attempts.	• Prospective ECG gated Volume • SURECardio Mode: Prospective CTA • kVp: 100-120 (Auto kV will select the lowest kVp to meet SUREExposure quality goal) • SUREExposure 3D: Cardiac CTA Standard ▸ SD: 33 ▸ Min mA: 40 ▸ Max mA: 500/800 (system dependent) ▸ Target Slice Thickness: 0.5 mm • Rotation Time: .275 sec./ .350 sec (fastest available per system) • Acquisition Thickness: 0.5 mm • DFOV: 250mm • CFOV: Large • Scan Direction: Superior-Inferior • Prospective Acquisition: SURECardio will auto-select based on patient HR Example: Systems with 0.275 sec. rotation: ▸ ≤75 BPM =70-80% R-R, 1 Beat (Half) ▸ 76-100 BPM = 35-55% R-R, 2 beat (Segmented) ▸ ≥101 BPM = 35-55% R-R, 3 beats (Segmented) Open the SURECardio menu and click the 'Breath Ex', this monitors the patient's heart rate during breath-hold training	SUREIQ Settings <u>Standard</u> • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: CTA Standard • Kernel: FC 03 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON <u>Sharp</u> • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: CTA Sharp • Kernel: FC 05 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON <u>Stent</u> • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: CTA Stent • Kernel: FC 50 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON

b. Timing: Acquiring the SURE Start S and V

General	Data Acquisition	Data Reconstruction
• OPTION You may prefer to trigger SURE Start using manual mode. Remember that you will still get a graphical readout of the ROI density. In manual mode, you can easily compensate for low cardiac output by delaying the start of scanning. Place the SURE Start ROI over the descending aorta. • Reassure the patient that it is normal to experience a sensation of warmth following contrast administration. Inform the patient that the next breath-hold is the last one for the examination. Confirm that the patient's heart rate is steady. It is a good idea to have someone monitor the first few seconds of contrast administration to avoid extravasation. Contrast injection and scanning are started simultaneously.	• Confirm that the descending aorta can be clearly identified on the SURE Start slice. • Place the SURE Start ROI over descending aorta as shown above • Set the SURE Start trigger at 180 HU	Set Scan Plan • S&V Slice: Center of the Volume ▸ If lock position is set to ON- the S&V position will automatically be set in the center of the Volume • CTA Volume: Cover carina through apex of the heart • If available, use the Calcium Score images to help select CTA start and end positions • DFOV 250 Review Parameters Click Confirm Perform S&V Acquisition Set SURE Start ROI • Set the SURE Start to 1 ROI, Automatic mode • Set the ROI 1 trigger value to 220-300 HU • Intermittent: Interval 2.0 sec, HU same as ROI 1 trigger value • Place the ROI in the descending aorta • ROI should be about half the size of the vessel Click Confirm Start the SURE Start Acquisition • Press the Start button on the keyboard to begin the SURE Start monitoring

c. Cardiac Reconstructions

General	Data Reconstruction
CTA: One Percent Phase or Millisecond reconstruction is made.  CFA: Multi Phase Percent or Millisecond Reconstructions.  PhaseXact: Is further broken down into three areas. 	PhaseXact +/- is available the parentheses ( ) show available phases. SUREIQ Settings Standard • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: Cardiac CTA Standard • Kernel: FC 03 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON Sharp • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: Cardiac CTA Sharp • Kernel: FC 05 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON

4. Contrast Protocol

General	Contrast Formula	Comments
The injection rate should be increased for shorter scan times and larger patients! CTA requires contrast medium with an iodine concentration of at least 350 mgI/mL. Place a 20- or 18-gauge IV cannula in the RIGHT arm. Set the SURE Start trigger at 180 HU	Biphasic Injection with Contrast/Saline Mix (Maintains right heart contrast for CFA) Phase 1 (Contrast) 60 mL @ 4 mL/s* (15s) @ 4 mL/s Phase 2 (Mix) 50% Contrast + 50% Saline XX= (Scan time s) x 4 (Simultaneous injection of contrast @ 2 mL/s & saline @ 2 mL/s) XX= (Scan Time s) x 4 In the above formula, the duration of mixed injection = scan time	Biphasic Injection with a Contrast/Saline Mix A biphasic injection protocol with a contrast/saline mix reduces streak artifact in the SVC and right heart, but maintains adequate opacification of the right ventricle. This may improve the detection of the ventricular septal wall for CFA.

* The injection rate should be increased for larger patients to ensure adequate iodine flux and therefore good arterial enhancement.

The following guidelines are suggested for injection rates:

Weight (kilograms)	Weight (pounds)	Injection Rate
<59 kg	<129 lb	3.5 mL/s
60-100 kg	130-219 lb	4 mL/s
>100 kg	>220 lb	5 mL/s

Review of Data Reconstruction and ECG-Editing

The concept of imageXact is to perform reconstruction at an absolute time point after the R wave (R + ms). Phase selection is performed using a single image located at the mid-heart level and reconstructed throughout the entire cardiac cycle.

- After the eXam Plan is completed, phaseXact finds and reconstructs the best motion-free cardiac phase. It may be necessary to reconstruct other phases to create a temporal window to permit better assessment of the proximal and distal arteries.
- imageXact-Guided image-based phase selection software
  In rare cases, phaseXact may not be able to automatically determine the best motion-free cardiac phase. In such cases, imageXact can help by guiding the operator through a simple and precise manual phase selection process.
- Image reconstructions of the heart should be reviewed immediately after the scan when raw data is still available.
- The ECG-gating should be reviewed to ensure that the automated algorithms correctly identified the R-peaks
- If R-peaks were not correctly identified, manual correction should be performed (e.g. add an R-peak if an R-peak was not identified, or delete an R-peak if an R-peak was placed on anything other than the R-peak; alternatively R-peaks can be shifted manually)
- In case of ectopic contractions, absolute ms reconstruction should be used and the R-peak of the ectopic beat should be deleted

ECG-editing screen showing correctly identified R-peaks.

4. Reference Protocol: Aquilion Prime SP, Aquilion Prime

1. Scanogram

General	Acquisition	Comments
Lateral and AP scout covering the heart and coronaries	• AP Scanogram: 120kVp/50mA • Lat Scanogram: 120kVp/100mA • Auto Voice: (breath hold command) 	Position the patient for AP scanogram to acquire AP and lateral scanograms. Offset the patient to the right so the heart is at the center of the scan field. Place the patient's arms above their head with the ECG leads outside the scan range. Attach the ECG Leads according to the manufacturer guidelines. • Ensure the ECG cables are clear of the gantry to prevent electronic interference • Perform an impedance check on ECG monitor to confirm good signal. • Place an 18- or 20-gauge IV cannula in the right antecubital vein. • Practice breath-holding with the patient at the tableside using the to ensure optimal compliance during the scan. Follow this link for an overview of the Ivy 7800 ECG monitor Have the patient practice breath holding before starting the examination. This should be a single "breathe in and hold" command. The patient should be instructed to hold their breath at about 75% of maximum lung capacity ("take a comfortable breath in") and to take the same size breath each time they are told. This important step has two purposes: To ensure that the patient can hold their breath for the required scan time. To monitor the patient's heart rate during breath-holding. Make sure that a steady heart rate is displayed with a clean ECG signal.

2. Non-enhanced Scan (optional) - Calcium Score

- Can be used for quantification of calcification
- Can be used for planning of subsequent contrast-enhanced data acquisition
- Volume data will be acquired as a single-beat/one rotation scan.
- Acquisition mode: Ca Score Volume Mode
- Tube Voltage: 120kVp
- SD: 60
- Min mA: 40
- Max mA: 300
- Target Slice Thickness: 0.5 mm
- Rotation Time: .350 sec (fastest available per system)
- Acquisition Thickness: 0.5 mm
- DFOV: 250mm
- CFOV: Large
- Scan Direction: Superior-Inferior
- Prospective Acquisition: SURECardio will auto-select based on patient HR
- ≤70 BPM =75% R-R
- ≥71 BPM = 40% R-R

DFOV: 220 mm

- Volume Slice Thickness/Interval: 0.5 x 0.25
- SUREIQ: Ca Score
- Kernel: FC 12
- Recon Process: AIDR 3D Standard or AIDR 3D Enhanced
- Xact+: ON

3. ECG Gated CTA

a. kV and mA

Genereal	Data Acquisition	Data Reconstruction

From the calcium scoring examination, select the start and end positions, the same scanogram can be used from the Calcium scan.
 	
It is advisable to plan 1 cm above the superior image selected and 1 cm below the inferior image selected in case the patient's breath-holding is inconsistent. Note: that the proximal LAD is often located superior to the origin of the left main coronary artery Can be used for quantification of calcification
 	
Click on the SURECardio button
 
 	
Perform Breath Exercise
 	
• The system will prompt to perform a breath exercise to optimize acquisition parameters
• SURECardio monitors the patient's heart rate during breath exercise. The acquisition parameters are optimized based on the HR detected during the breath hold
• If the patient's heart rate changes by more than 10% during the breath exercise, perform additional breath exercise until the heart rate stabilizes. Be sure to give time for the patient to relax between attempts.
	• Prospective ECG gated Volume
	• SURECardio Mode: Prospective CTA
	• kVp: 100-120 (Auto kV will select the lowest kVp to meet SUREExposure quality goal)
	• SUREExposure 3D: Cardiac CTA Standard
	  ▸ SD: 33
	  ▸ Min mA: 40
	  ▸ Max mA: 500/800 (system dependent)
	  ▸ Target Slice Thickness: 0.5 mm
	• Rotation Time: .275 sec./ .350 sec (fastest available per system)
	• Acquisition Thickness: 0.5 mm
	• DFOV: 250mm
	• CFOV: Large
	• Scan Direction: Superior-Inferior
	• Prospective Acquisition: SURECardio will auto-select based on patient HR Example: Systems with 0.275 sec. rotation:
	  ▸ ≤75 BPM =70-80% R-R, 1 Beat (Half)
	  ▸ 76-100 BPM = 35-55% R-R, 2 beat (Segmented)
	  ▸ ≥101 BPM = 35-55% R-R, 3 beats (Segmented)
	
	Open the SURECardio menu and click the 'Breath Ex', this monitors the patient's heart rate during breath-hold training
		SUREIQ Settings
		
		<u>Standard</u>
		• DFOV: 250 mm
		• Volume Slice Thickness/Interval: 0.5 x 0.25
		• SUREIQ: CTA Standard
		• Kernel: FC 03
		• Recon Process: AIDR 3D Standard or AIDR 3D Enhanced
		• Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard
		• Xact+: ON
		
		<u>Sharp</u>
		• DFOV: 250 mm
		• Volume Slice Thickness/Interval: 0.5 x 0.25
		• SUREIQ: CTA Sharp
		• Kernel: FC 05
		• Recon Process: AIDR 3D Standard or AIDR 3D Enhanced
		• Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard
		• Xact+: ON
		
		<u>Stent</u>
		• DFOV: 250 mm
		• Volume Slice Thickness/Interval: 0.5 x 0.25
		• SUREIQ: CTA Stent
		• Kernel: FC 50
		• Recon Process: AIDR 3D Standard or AIDR 3D Enhanced
		• Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard
		• Xact+: ON

b. Timing: Acquiring the SURE Start S and V

General	Data Acquisition	Data Reconstruction
• OPTION You may prefer to trigger SURE Start using manual mode. Remember that you will still get a graphical readout of the ROI density. In manual mode, you can easily compensate for low cardiac output by delaying the start of scanning. Place the SURE Start ROI over the descending aorta as. • Reassure the patient that it is normal to experience a sensation of warmth following contrast administration. Inform the patient that the next breath-hold is the last one for the examination. Confirm that the patient's heart rate is steady. It is a good idea to have someone monitor the first few seconds of contrast administration to avoid extravasation. Contrast injection and scanning are started simultaneously.	• Confirm that the descending aorta can be clearly identified on the SURE Start slice. • Place the SURE Start ROI over the descending aorta as shown above • Set the SURE Start trigger at 180 HU	Set Scan Plan • S&V Slice: Center of the Volume ▸ If lock position is set to ON- the S&V position will automatically be set in the center of the Volume • CTA Volume: Cover carina through apex of the heart • If available, use the Calcium Score images to help select CTA start and end positions • DFOV 250 Review Parameters Click Confirm Perform S&V Acquisition Set SURE Start ROI • Set the SURE Start to 1 ROI, Automatic mode • Set the ROI 1 trigger value to 220-300 HU • Intermittent: Interval 2.0 sec, HU same as ROI 1 trigger value • Place the ROI in the descending aorta • ROI should be about half the size of the vessel Click Confirm Start the SURE Start Acquisition • Press the Start button on the keyboard to begin the SURE Start monitoring

c. Cardiac Reconstructions

General	Data Reconstruction
CTA: One Percent Phase or Millisecond reconstruction is made.  CFA: Multi Phase Percent or Millisecond Reconstructions.  PhaseXact: Is further broken-down into three areas.  	PhaseXact +/- is available the parentheses ( ) show available phases. SUREIQ Settings <u>Standard</u> • In Cardiac Standard and Cardiac Sharp SUREIQ • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: Cardiac CTA Standard • Kernel: FC 03 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON <u>Sharp</u> • DFOV: 250 mm • Volume Slice Thickness/Interval: 0.5 x 0.25 • SUREIQ: Cardiac CTA Sharp • Kernel: FC 05 • Recon Process: AIDR 3D Standard or AIDR 3D Enhanced • Recon Process (Option): AiCE Cardiac Standard, PIQE Cardiac Standard • Xact+: ON

4. Contrast Protocol

General	Contrast Formula	Comments
The injection rate should be increased for shorter scan times and larger patients! CTA requires contrast medium with an iodine concentration of at least 350 mgI/mL. Place a 20- or 18-gauge IV cannula in the RIGHT arm.	Biphasic Injection with Contrast/Saline Mix (Maintains right heart contrast for CFA) Phase 1 (Contrast) 60 mL @ 4 mL/s* (15 s) @ 4 mL/s Phase 2 (Mix) 50% Contrast + 50% Saline XX = (Scan Time s) x 4 (Simultaneous injection of contrast @2mL/s & saline @2mL/s) XX = (Scan Time s) x 4 In the above formula, the duration of mixed injection = scan time	Biphasic Injection with a Contrast/Saline Mix A biphasic injection protocol with a contrast/saline mix reduces streak artifact in the SVC and right heart, but maintains adequate opacification of the right ventricle. This may improve the detection of the ventricular septal wall for CFA.

* The injection rate should be increased for larger patients to ensure adequate iodine flux and therefore good arterial enhancement.

The following guidelines are suggested for injection rates:

Weight (kilograms)	Weight (pounds)	Injection Rate
<59 kg	<129 lb	3.5 mL/s
60-100 kg	130-219 lb	4 mL/s
>100 kg	>220 lb	5 mL/s

Review of Data Reconstruction and ECG-Editing

- Image reconstructions of the heart should be reviewed immediately after the scan when raw data is still available
- The ECG-gating should be reviewed to ensure that the automated algorithms correctly identified the R-peaks
- If R-peaks were not correctly identified, manual correction should be performed (e.g. add an R-peak if an R-peak was not identified, or delete an R-peak if an R-peak was placed on anything other than the R-peak; alternatively R-peaks can be shifted manually)
- In case of ectopic contractions, absolute ms reconstruction should be used and the R-peak of the ectopic beat should be deleted

ECG-editing screen showing correctly identified R-peaks.

5. Bibliography

1. Dewey M, Hoffmann H, Hamm B. Multislice CT coronary angiography: effect of sublingual nitroglycerine on the diameter of coronary arteries. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2006;178(6):600-4.
2. Decramer I, Vanhoenacker PK, Sarno G, Van Hoe L, Bladt O, Wijns W, et al. Effects of sublingual nitroglycerin on coronary lumen diameter and number of visualized septal branches on 64-MDCT angiography. American Journal of Roentgenology. 2008;190(1):219-25.
3. Laslett LJ, Baker L. Sublingual nitroglycerin administered by spray versus tablet: comparative timing of hemodynamic effects. Cardiology. 1990;77(4):303-10.
4. Bachmann KF, Gansser RE. Nitroglycerin oral spray: evaluation of its coronary artery dilative action by quantitative angiography. The American journal of cardiology. 1988;61(9):7E-11E.
5. Sato K, et al. Optimal starting time of acquisition and feasibility of complementary administration of nitroglycerin with intravenous beta-blocker in multislice computed tomography. JCCT. 2009;33(2):193)
6. Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, Marwan M, Naoum C, Norgaard BL, Rubinshtein R, Schoenhagen P, Villines T, Leipsic J. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). J Cardiovasc Comput Tomogr. 2016 Oct 12. pii: S1934-5925(16)30239-8.
7. Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. Journal of cardiovascular computed tomography. 2014;8(5):342-58.
8. Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. Journal of the American College of Cardiology. 2008;52(21):1724-32.
9. Meijboom WB, Meijs MF, Schuijf JD, Cramer MJ, Mollet NR, van Mieghem CA, et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. Journal of the American College of Cardiology. 2008;52(25):2135-44.
10. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et al. Diagnostic performance of coronary angiography by 64-row CT. The New England journal of medicine. 2008;359(22):2324-36.
11. Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. Journal of the American College of Cardiology. 2007;50(12):1161-70.
12. Min JK, Dunning A, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. Journal of the American College of Cardiology. 2011;58(8):849-60.
13. Villines TC, Hulten EA, Shaw LJ, Goyal M, Dunning A, Achenbach S, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. Journal of the American College of Cardiology. 2011;58(24):2533-40.
14. Leipsic J, Taylor CM, Gransar H, Shaw LJ, Ahmadi A, Thompson A, et al. Sex-based prognostic implications of nonobstructive coronary artery disease: results from the international multicenter CONFIRM study. Radiology. 2014;273(2):393-400.
15. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O'Gara P, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology. 2010;56(22):1864-94.

16. Jacobs JE, Boxt LM, Desjardins B, Fishman EK, Larson PA, Schoepf J, et al. ACR practice guideline for the performance and interpretation of cardiac computed tomography (CT). Journal of the American College of Radiology : JACR. 2006;3(9):677-85.
17. Halliburton SS, Abbara S, Chen MY, Gentry R, Mahesh M, Raff GL, et al. SCCT guidelines on radiation dose and dose-optimization strategies in cardiovascular CT. Journal of cardiovascular computed tomography. 2011;5(4):198-224.
18. Valentin J. Pregnancy and medical radiation: ICRP publication 84. . Ann ICRP 2000(30(1)):1-39.
19. Chen MM, Coakley FV, Kaimal A, Laros RK, Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112(2 Pt 1):333-340.
20. Woussen S1, Lopez-Rendon X, Vanbeckevoort D, Bosmans H, Oyen R, Zanca F. Clinical indications and radiation doses to the conceptus associated with CT imaging in pregnancy: a retrospective study. Eur Radiol. 2015 Jul 23.
21. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital R. The use of iodinated and gadolinium contrast media during pregnancy and lactation. European radiology. 2005;15(6):1234-40.
22. Rubin G, Bluemke D, Duerinckx A, Flamm S, Grist T, Jacobs J, et al. ACR Committee on Cardiac Imaging. Practice guideline for the performance and interpretation of cardiac computed tomography (CT). (Res. 10, 16g, 17, 34, 35, 36 – 2006) In: Practice Guidelines and Technical Standards. Reston, VA: American College of Radiology. 2008;421-30.
23. Greenberger P, Patterson R. Prednisone-diphenhydramine regimen prior to use of radiographic contrast media. The Journal of allergy and clinical immunology. 1979;63(4):295.
24. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995;92(5):1094-100.
25. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL, Jr., Lopez AG, Winniford MD. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. Journal of the American College of Cardiology. 1993;22(3):642-7.
26. Elicker BM, Cypel YS, Weinreb JC. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR American journal of roentgenology. 2006;186(6):1651-8.
27. Lee JK, Warshauer DM, Bush WH, Jr., McClennan BL, Choyke PL. Determination of serum creatinine level before intravenous administration of iodinated contrast medium. A survey. Investigative radiology. 1995;30(12):700-5.
28. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 2014;65(2):96-105.
29. Owen at al. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J. 2014 May;65(2):96-105
30. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211-7.
31. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. European heart journal. 2004;25(3):206-11.
32. Lee PT, Chou KJ, Liu CP, Mar GY, Chen CL, Hsu CY, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. Journal of the American College of Cardiology. 2007;50(11):1015-20.
33. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. The New England journal of medicine. 2006;354(26):2773-82.
34. McDonald R, Mdcondal J, Bida Jet al Intravenous Contrast Material–induced Nephropathy:
35. Causal or Coincident Phenomenon?. RadiologyVolume 267: Number 1—April 2013
36. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR American journal of roentgenology. 2008;191(2):376-82.
37. McDonald RJ, McDonald JS, Carter RE, Hartman RP, Katzberg RW, Kallmes DF, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology. 2014;273(3):714-25.
38. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 2014;65(2):96-105.
39. Ahuja TS, Niaz N, Agraharkar M. Contrast-induced nephrotoxicity in renal allograft recipients. Clinical nephrology. 2000;54(1):11-4.

40. Brodoefel H, Reimann A, Heuschmid M, Kuttner A, Beck T, Burgstahler C, et al. Non-invasive coronary angiography with 16-slice spiral computed tomography: image quality in patients with high heart rates. European radiology. 2006;16(7):1434-41.
41. Cademartiri F, Mollet NR, Runza G, Belgrano M, Malagutti P, Meijboom BW, et al. Diagnostic accuracy of multislice computed tomography coronary angiography is improved at low heart rates. The international journal of cardiovascular imaging. 2006;22(1):101-5; discussion 7-9.
42. Achenbach S, Manolopoulos M, Schuhback A, Ropers D, Rixe J, Schneider C, et al. Influence of heart rate and phase of the cardiac cycle on the occurrence of motion artifact in dual-source CT angiography of the coronary arteries. Journal of cardiovascular computed tomography. 2012;6(2):91-8.
43. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of the American College of Cardiology. 2007;49(2):171-80.
44. 44. Maffei E, Palumbo AA, Martini C, Tedeschi C, Tarantini G, Seitun S, et al. "In-house" pharmacological management for computed tomography coronary angiography: heart rate reduction, timing and safety of different drugs used during patient preparation. European radiology. 2009;19(12):2931-40.
45. Roberts WT, Wright AR, Timmis JB, Timmis AD. Safety and efficacy of a rate control protocol for cardiac CT. The British journal of radiology. 2009;82(976):267-71.
46. Earls et al JCCT Metoprolol
47. Sadamatsu K, Koide S, Nakano K, Yoshida K. Heart rate control with single administration of a long-acting beta-blocker at bedtime before coronary computed tomography angiography. Journal of cardiology. 2015;65(4):293-7.
48. Clayton B, Raju V, Roobottom C, Morgan-Hughes G. Safety of intravenous beta-adrenoceptor blockers for computed tomographic coronary angiography. British journal of clinical pharmacology. 2015;79(3):533-6.
49. Kassamali RH, Kim DH, Patel H, Raichura N, Hoey ET, Hodson J, et al. Safety of an i.v. beta-adrenergic blockade protocol for heart rate optimization before coronary CT angiography. AJR American journal of roentgenology. 2014;203(4):759-62.
50. Wang JD, Zhang HW, Xin Q, Yang JJ, Sun ZJ, Liu HB, et al. Safety and efficacy of intravenous esmolol before prospective electrocardiogram-triggered high-pitch spiral acquisition for computed tomography coronary angiography. Journal of geriatric cardiology : JGC. 2014;11(1):39-43.
51. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. European journal of heart failure. 2014;16(1):76-85.
52. Pichler P, Pichler-Cetin E, Vertesich M, Mendel H, Sochor H, Dock W, et al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. The American journal of cardiology. 2012;109(2):169-73.
53. Celik O, Atasoy MM, Erturk M, Yalcin AA, Aksu HU, Diker M, et al. Comparison of different strategies of ivabradine premedication for heart rate reduction before coronary computed tomography angiography. Journal of cardiovascular computed tomography. 2014;8(1):77-82.
54. Guaricci AI, Schuijf JD, Cademartiri F, Brunetti ND, Montrone D, Maffei E, et al. Incremental value and safety of oral ivabradine for heart rate reduction in computed tomography coronary angiography. International journal of cardiology. 2012;156(1):28-33.
55. Guaricci AI, Maffei E, Brunetti ND, Montrone D, Di Biase L, Tedeschi C, et al. Heart rate control with oral ivabradine in computed tomography coronary angiography: a randomized comparison of 7.5 mg vs 5 mg regimen. International journal of cardiology. 2013;168(1):362-8.
56. Adile KK, Kapoor A, Jain SK, Gupta A, Kumar S, Tewari S, et al. Safety and efficacy of oral ivabradine as a heart rate-reducing agent in patients undergoing CT coronary angiography. The British journal of radiology. 2012;85(1016):e424-8.
57. Cademartiri F, Garot J, Tendera M, Zamorano JL. Intravenous ivabradine for control of heart rate during coronary CT angiography: A randomized, double-blind, placebo-controlled trial. Journal of cardiovascular computed tomography. 2015;9(4):286-94.
58. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. The New England journal of medicine. 1998;338(8):520-31.
59. Dewey M, Hoffmann H, Hamm B. Multislice CT coronary angiography: effect of sublingual nitroglycerine on the diameter of coronary arteries. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2006;178(6):600-4.
60. Decramer I, Vanhoenacker PK, Sarno G, Van Hoe L, Bladt O, Wijns W, et al. Effects of sublingual nitroglycerin on coronary lumen diameter and number of visualized septal branches on 64-MDCT angiography. AJR American journal of roentgenology. 2008;190(1):219-25.
61. Laslett LJ, Baker L. Sublingual nitroglycerin administered by spray versus tablet: comparative timing of hemodynamic effects. Cardiology. 1990;77(4):303-10.

62. Bachmann KF, Gansser RE. Nitroglycerin oral spray: evaluation of its coronary artery dilative action by quantitative angiography. The American journal of cardiology. 1988;61(9):7E-11E.
63. Sato K, et al. Optimal starting time of acquisition and feasibility of complementary administration of nitroglycerin with intravenous beta-blocker in multislice computed tomography. JCCT. 2009;33(2):193)
64. Chun EJ et al J. Effects of nitroglycerin on the diagnostic accuracy of electrocardiogram-gated coronary computed tomography angiography. JCCT. 2008;32(1):86-92)
65. Wang G, Vannier MW. Spatial variation of section sensitivity profile in spiral computed tomography. Medical physics. 1994;21(9):1491-7.
66. Ohnesorge B, Flohr T, Becker C, Kopp AF, Schoepf UJ, Baum U, et al. Cardiac imaging by means of electrocardiographically gated multisection spiral CT: initial experience. Radiology. 2000;217(2):564-71.
67. Halliburton SS, Abbara S. Practical tips and tricks in cardiovascular computed tomography: patient preparation for optimization of cardiovascular CT data acquisition. Journal of cardiovascular computed tomography. 2007;1(1):62-5.
68. Bae KT, Tran HQ, Heiken JP. Multiphasic injection method for uniform prolonged vascular enhancement at CT angiography: pharmacokinetic analysis and experimental porcine model. Radiology. 2000;216(3):872-80.
69. Fleischmann D, Rubin GD, Bankier AA, Hittmair K. Improved uniformity of aortic enhancement with customized contrast medium injection protocols at CT angiography. Radiology. 2000;214(2):363-71.
70. Haage P, Schmitz-Rode T, Hubner D, Piroth W, Gunther RW. Reduction of contrast material dose and artifacts by a saline flush using a double power injector in helical CT of the thorax. AJR American journal of roentgenology. 2000;174(4):1049-53.
71. Hopper KD, Mosher TJ, Kasales CJ, TenHave TR, Tully DA, Weaver JS. Thoracic spiral CT: delivery of contrast material pushed with injectable saline solution in a power injector. Radiology. 1997;205(1):269-71.
72. Raju R, Thompson AG, Lee K, Precious B, Yang TH, Berger A, et al. Reduced iodine load with CT coronary angiography using dual-energy imaging: a prospective randomized trial compared with standard coronary CT angiography. Journal of cardiovascular computed tomography. 2014;8(4):282-8.
73. Carrascosa P, Leipsic JA, Capunay C, Deviggiano A, Vallejos J, Goldsmit A, et al. Monochromatic image reconstruction by dual energy imaging allows half iodine load computed tomography coronary angiography. European journal of radiology. 2015.
74. Yin WH, Lu B, Gao JB, Li PL, Sun K, Wu ZF, et al. Effect of reduced x-ray tube voltage, low iodine concentration contrast medium, and sinogram-affirmed iterative reconstruction on image quality and radiation dose at coronary CT angiography: results of the prospective multicenter REALISE trial. Journal of cardiovascular computed tomography. 2015;9(3):215-24.
75. Hein PA, May J, Rogalla P, Butler C, Hamm B, Lembcke A. Feasibility of contrast material volume reduction in coronary artery imaging using 320-slice volume CT. European radiology. 2010;20(6):1337-43.
76. Kim R, et al. Feasibility of 320-row CT coronary angiography using 40 mL…Eur Radiol. 2016; Feb 23 (Epub ahead of print).
77. Marwan et al Radiology High Pitch TAVR
78. Segal A, Ellis J, Baumgartner B, Choyke P, Cohan R, Costouros N, et al. ACR Committee on Drugs and Contrast Media. Practice guideline for the use of intravascular contrast media. (Res. 38 – 2007) In: Practice Guidelines and Technical Standards. Reston, VA: . American College of Radiology. 2008;73-78.
79. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(24):13761-6.
80. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation; Nuclear and Radiation Studies Board, Division on Earth and Life Studies, National Research Council of the National Academies. Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press. 2006.
81. Don S. Radiosensitivity of children: potential for overexposure in CR and DR and magnitude of doses in ordinary radiographic examinations. Pediatric radiology. 2004;34 Suppl 3:S167-72; discussion S234-41.
82. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA : the journal of the American Medical Association. 2007;298(3):317-23.
83. Deseive S, Chen MY, Korosoglou G, Leipsic J, Martuscelli E, Carrascosa P, et al. Prospective Randomized Trial on Radiation Dose Estimates of CT Angiography Applying Iterative Image Reconstruction: The PROTECTION V Study. JACC Cardiovascular imaging. 2015;8(8):888-96.
84. Deseive S, Pugliese F, Meave A, Alexanderson E, Martinoff S, Hadamitzky M, et al. Image quality and radiation dose of a prospectively electrocardiography-triggered high-pitch data acquisition strategy for coronary CT angiography: The multicenter, randomized PROTECTION IV study. Journal of cardiovascular computed tomography. 2015;9(4):278-85.

85. Hausleiter J, Martinoff S, Hadamitzky M, Martuscelli E, Pschierer I, Feuchtner GM, et al. Image quality and radiation exposure with a low tube voltage protocol for coronary CT angiography results of the PROTECTION II Trial. JACC Cardiovascular imaging. 2010;3(11):1113-23.
86. Hausleiter J, Meyer TS, Martuscelli E, Spagnolo P, Yamamoto H, Carrascosa P, et al. Image quality and radiation exposure with prospectively ECG-triggered axial scanning for coronary CT angiography: the multicenter, multivendor, randomized PROTECTION-III study. JACC Cardiovascular imaging. 2012;5(5):484-93.
87. Chen MY, et al. Submillisievert median radiation dose for coronary angiography with a second-generation 320-detector row CTscanner in 107 consecutive patients. Radiology. 2013 Apr;267(1):76-85. doi: 10.1148/radiol.13122621. Epub 2013 Jan 22.
88. Zhao L, Plank F, Kummann M, Burghard P, Klauser A, Dichtl W, Feuchtner G. Improved non-calcified plaque delineation on coronary CT angiography by sonogram-affirmed iterative reconstruction withdifferent filter strength and relationship with BMI. Cardiovasc Diagn Ther. 2015 Apr;5(2):104-12.
89. Task Group on Control of Radiation Dose in Computed T. Managing patient dose in computed tomography. A report of the International Commission on Radiological Protection. Annals of the ICRP. 2000;30(4):7-45.
90. Hausleiter J, Meyer T, Hadamitzky M, Huber E, Zankl M, Martinoff S, et al. Radiation dose estimates from cardiac multislice computed tomography in daily practice: impact of different scanning protocols on effective dose estimates. Circulation. 2006;113(10):1305-10.
91. Siegel MJ, Schmidt B, Bradley D, Suess C, Hildebolt C. Radiation dose and image quality in pediatric CT: effect of technical factors and phantom size and shape. Radiology. 2004;233(2):515-22.
92. Leipsic J, LaBounty TM, Mancini GB, Heilbron B, Taylor C, Johnson MA, et al. A prospective randomized controlled trial to assess the diagnostic performance of reduced tube voltage for coronary CT angiography. AJR American journal of roentgenology. 2011;196(4):801-6.
93. Oda S, Utsunomiya D, Funama Y, Yonenaga K, Namimoto T, Nakaura T, et al. A hybrid iterative reconstruction algorithm that improves the image quality of low-tube-voltage coronary CT angiography. AJR American journal of roentgenology. 2012;198(5):1126-31.
94. Williams MC, Weir NW, Mirsadraee S, Millar F, Baird A, Minns F, et al. Iterative reconstruction and individualized automatic tube current selection reduce radiation dose while maintaining image quality in 320-multidetector computed tomography coronary angiography. Clinical radiology. 2013;68(11):e570-7.
95. Deseive S, Pugliese F, Meave A, Alexanderson E, Martinoff S, Hadamitzky M, et al. Image quality and radiation dose of a prospectively electrocardiography-triggered high-pitch data acquisition strategy for coronary CT angiography: The multicenter, randomized PROTECTION IV study. Journal of cardiovascular computed tomography. 2015;9(4):278-85.

HeartFlow®

331 E Evelyn Ave, Mountain View, CA 94041
ph: +1.650.241.1221 | info@heartflow.com | heartflow.com

15991228 V3